Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
复制标题
DOI：
10.1016/j.bbmt.2008.12.497
复制
发表时间：
2009-03
期刊：
影响因子：
--
通讯作者：
Sandmaier B
中科院分区：
文献类型：
--
作者：
Giralt S;Ballen K;Rizzo D;Bacigalupo A;Horowitz M;Pasquini M;Sandmaier B
在2006年Tandem BMT会议期间，国际血液和骨髓移植研究中心（CIBMTR）召开了一次研讨会，讨论预处理方案强度，并确定造血细胞移植（HCT）前“降低强度预处理”（RIC）的界限。研讨会的目标是确定移植界对现有RIC定义的接受程度。在研讨会期间对参与者进行了调查，以说明他们是否强烈同意、同意、不同意或强烈不同意关于调理方案强度的具体陈述。这些问题包括“Champlin标准”以及临床小插图中举例说明的登记研究中使用的操作定义。五十六名参与者回答了调查，包括移植医生，移植中心主任和移植护士，平均12年的HCT经验。67%的人同意RIC方案在没有干细胞支持的情况下给药时应引起可逆的骨髓抑制;导致低非血液学毒性，并且在大多数患者首次评估时移植后导致混合供体-受体嵌合体。同样，大多数人（71%）同意或强烈同意，全身照射剂量低于500 cGy（单次）或800 cGy（分次剂量）、白消安低于9 mg/kg、美法仑低于140 mg/m2或塞替派低于10 mg/kg的方案应被视为RIC方案。然而，只有32%的人同意或强烈同意卡莫司汀、依托泊苷、阿糖胞苷和美法仑（BEAM）联合治疗被视为RIC方案。这些结果表明，尽管HCT专业人员对RIC方案的构成没有达成共识，但他们中的大多数人接受了目前使用的标准和操作定义。这些结果支持继续使用RIC方案的当前标准，直到达成共识声明。
During the 2006 Tandem BMT Meetings a workshop was convened by the Center for International Blood and Marrow Transplant Research (CIBMTR) to discuss conditioning regimen intensity and define boundaries of “reduced intensity conditioning” (RIC) prior to hematopoietic cell transplantation (HCT). The goal of the workshop was to determine acceptance within the transplant community of available RIC definitions. The participants were surveyed during the workshop to state if they strongly agreed, agreed, disagreed or strongly disagreed with specific statements on conditioning regimen intensity. The questions included the “Champlin criteria” as well as operational definitions used in registries studies exemplified in clinical vignettes. Fifty-six participants including transplant physicians, transplant center directors and transplant nurses with a median of 12 years of experience in HCT answered the survey. Sixty-seven percent agreed with statements that a RIC regimen should cause reversible myelosuppression when administered without stem cell support; result in low non-hematologic toxicity and after transplantation results in mixed donor-recipient chimerism at the time of first assessment in the majority of patients. Likewise the majority (71%) agreed or strongly agreed that regimens with less than 500 cGy of total body irradiation as a single fraction or 800 cGy in fractionated doses, busulfan less than 9 mg/kg, melphalan less than 140 mg/m2 or thiotepa less than 10 mg/kg should be considered RIC regimens. However, only 32% agreed or strongly agreed that the combination of carmustine, etoposide, cytarabine and melphalan (BEAM) be considered a RIC regimen. These results demonstrate that although a consensus of what constitutes a RIC regimen does not exist among HCT professionals, currently used criteria and operational definitions are accepted by a majority of them. These results support the continued use of current criteria for RIC regimens until a consensus statement is developed.
登录
查看更多内容
影响因子：
4.8
作者：
Bacigalupo, A
通讯作者：
Bacigalupo, A
影响因子：
20.3
作者：
Slavin, S;Nagler, A;Or, R
通讯作者：
Or, R
影响因子：
11.4
作者：
Storb, R
通讯作者：
Storb, R
影响因子：
45.3
作者：
Khouri, IF;Keating, M;Champlin, R
通讯作者：
Champlin, R
影响因子：
6.5
作者：
Raiola, AM;Van Lint, MT;Bacigalupo, A
通讯作者：
Bacigalupo, A